ResMed Expands COPD Offering As New Data Reveals Benefits Of Home Non-Invasive Ventilation

• New research released at European Respiratory Society (ERS) International Congress 2016 highlights the benefits of home non-invasive ventilation (NIV), with the potential to positively impact current practice and improve the lives of patients with COPD
• ResMed at-home COPD management portfolio now includes portable oxygen therapy, alongside home NIV and remote monitoring technology

LONDON--(BUSINESS WIRE)--Today ResMed welcomed positive results from the independent Home Oxygen Therapy- Home Mechanical Ventilation (HOT-HMV) study¹ regarding the benefits of home non-invasive ventilation (NIV). Portable oxygen therapy, remote monitoring technology and home NIV are key components of ResMed’s COPD management offering.

“We hope these results will have a positive impact on current practice and encourage more healthcare professionals to consider the role of home NIV in managing their COPD patients.”

The HOT-HMV study shows that the addition of home NIV to home oxygen therapy improves admission-free survival in hypercapnic COPD patients (those with high levels of carbon dioxide in the blood) following a life-threatening exacerbation of COPD requiring acute NIV.¹ This includes an increase in patients’ median (hospital) admission-free survival from 1.4 months in the group receiving HOT only, to 4.3 months in the group receiving HOT plus home NIV, with an adjusted hazard ratio of 0.49 (0.31-0.77); p=0.002.¹

“These results build on and add further weight to existing evidence supporting the broader use of home NIV in patients living with COPD, whilst also underlining the accepted benefits of home NIV in terms of reducing hospital admissions and improving patient outcomes,” said Holger Woehrle, ResMed’s Vice President of Clinical Research and Medical Director of EMEA & APAC. “We hope these results will have a positive impact on current practice and encourage more healthcare professionals to consider the role of home NIV in managing their COPD patients.”

Previous studies also confirm that home NIV can successfully reduce mortality² and exacerbation-related hospitalisations³ and improve patients’ quality of life.²

ResMed’s at-home COPD offering includes three series of home NIV products, Lumis™, Stellar™ and Astral™, which can be used by COPD patients at different stages of their disease. These solutions ensure pulmonologists can efficiently meet the unique and ever-changing needs of their COPD patients whilst also optimising healthcare professionals’ time and resources.

ResMed home NIV solutions are also connected to AirView™, ResMed’s cloud-based patient management system, which ensures healthcare professionals can remotely identify patients in need of attention, make informed treatment decisions and deliver timely interventions. In addition to helping physicians better manage COPD patients on home NIV, AirView also enables home care providers to optimise business efficiencies and allows them to focus existing resources on high-value activities. Resmed’s cloud-connected ventilators provide peace of mind to patients and their families and help improve their overall experience living with COPD.

With the ambition of improving the lives of more and more patients, ResMed has this week unveiled the newest addition to its growing COPD portfolio: LifeChoice^TM Activox 4L^TM portable oxygen concentrator from Inova Labs, which ResMed acquired in early 2016. Highly portable, with class-leading battery autonomy, LifeChoice Activox 4L is less intrusive than traditional oxygen delivery formats. It can help COPD patients who are still mobile to overcome the constraints that options such as tanks and Liquid O₂ place on their day-to-day activities. Specially designed for patient comfort, this new solution also allows patients to benefit from smoother oxygen delivery.

“COPD is a debilitating, chronic condition and we have made it our mission as a company to help all COPD patients remain as active and independent as they can be for as long as possible,” said Luke Maguire, ResMed’s President of Cardio-Respiratory Care. “ResMed is proud to take an active role in supporting our partners in the pulmonology community to deliver new at-home technologies that can help to achieve this across the COPD management spectrum – from oxygen therapy, to non-invasive ventilation and remote monitoring.”

About COPD

Chronic obstructive pulmonary disorder, or COPD, describes a collection of lung diseases including chronic bronchitis, emphysema and chronic obstructive airways disease. It is a progressive, fatal condition that causes irreversible damage to the lungs and airway. COPD leads to difficulty breathing and can have a major impact on an individual’s quality of life. It is one of the leading causes of death worldwide and is the only major disease that is increasing in prevalence globally, across all continents.^4,5,6 During the course of their disease, COPD patients can experience acute exacerbations, which manifest themselves as a sudden worsening of symptoms and can lead to respiratory failure, hospitalisation and death. Although the damage caused by COPD cannot be reversed, it is possible to slow the progression of the disease through medical treatment and lifestyle changes.

About ResMed

ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnoea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 2 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.

ResMed.com | Facebook | Twitter | LinkedIn

References

1 Murphy P. and Hart N. Home Mechanical Ventilation (HMV) Following Life Threatening Exacerbations of COPD: A UK Multicentre Randomised Controlled Trial. Abstract presented at the European Respiratory Society annual congress 2016, London.

2 Köhnlein T, et al. Lancet Respir Med. 2014;2 :698-705

3 Galli J, Krahnke JS, James Mamary A, Shenoy K, Zhao H, Criner GJ. Home non-invasive ventilation use following acute hypercapnic respiratory failure in COPD. Respir Med. 2014 May;108(5):722-8. doi: 10.1016/j.rmed.2014.03.006. Epub 2014 Mar 20.

4 Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. Int J Tuberc Lung Dis 2008; 12: 703–708.

5 Menezes AM, Jardim JR, Peréz-Padilla R, et al. Prevalence of chronic obstructive pulmonary disease and associated factors: the PLATINO Study in Sao Paulo, Brazil. Cad Saude Publica 2005; 21: 1565–1573.

6 Mehrotra A, Oluwole AM, Gordon SB. The burden of COPD in Africa: a literature review and prospective survey of the availability of spirometry for COPD diagnosis in Africa. Trop Med Int Health 2009; 14: 840–848